Catedrática
Phone. +34 91 585 4380
Fax. +34 91 585 4441
E-mail. misanchez@iib.uam.es - is.perez@uam.es
Website IIBM: Isabel Sánchez Pérez Lab
Website Portal Producción Científica UAM. Isabel Sánchez Pérez
CIBERER. CIBERER
Dr. Isabel Sánchez, obtained her PhD degree in 1998, followed by a postdoctoral period in Spain and a short-term fellowship in Sir Dr. Paul Nurse´s lab. Next, she moved to London in 2003 as a postdoctoral fellow at the National Institute for Medical Research (MRC). After two years, she established her independent laboratory back as a Ramon y Cajal Researcher in Madrid, where she followed her interest on the study of chromosome instability and the therapeutic response in cancer disease. She is now appointed as Associate Professor in the Department of Biochemistry, at the Medical School of the Autonomous University in Madrid
As an academic, Dr. Sanchez-Perez participates in multiple teaching activities of the Bachelor degree programs at the Biochemistry and Medicine areas, with special focus on research training.
PhD student: Jone Bargiela Iparragirre
Title: Role of Mad2 in Gastric Cancer: Potential biomarker of response
to therapy.
Year: ongoing
University: Universidad Autónoma De Madrid (UAM) Universidad Autónoma
De Mexico (UNAM).
PhD student: Natalia Pajuelo Lozano
Title: Coordination between G2 checkpoints and mitosis in response to
therapy in gastric cancer.
University: Universidad Autónoma De Madrid (UAM) Universidad Autónoma
De Mexico (UNAM).
School: Medicine
Year: ongoing
2017-Present Associate professor UAM
2014-2016 Associate Researcher UAM.
2010-2014 Profesor contratado doctor.
2006-2010 Ramon y Cajal Research Fellow. UAM.
2003-2006 Postdoctoral Research Fellow at National Institute for Medical
Research (MRC) London UK.
1998-2002 Postdoctoral Research Fellow at CSIC (IIBM-CSIC), Comunidad
de Madrid.
1995-1998 PhD student (FPU fellowship) at IIB-CSIC.
Gastric cancer (GC) is still the fourth main cause of cancer related death all over the world. Its high prevalence and the lack of efficient personalized treatments make it a mayor cause of public health concern. In GC, adenocarcinomas gastrectomy is the only curative treatment currently available, and it is frequently combined with adjuvant radio/chemotherapy. Thus, despite of recent improvements in care, there is still an imperative need to improve GC available treatments. Given the lack of good biomarkers for therapy response and patient prognosis, our focus of interest is to gain insight into the molecular pathways that condition the response to specific therapies in GC cell models. During the last years we have been analysing the correlation between Chromosomal Instability (CIN) and response to therapy in GC. The main area of interest of our laboratory is the study of biomarkers, which can help us predict the response to specific chemotherapy treatment regimes. We have shown that in GC the Chk2 protein has a crucial role in the response to the treatment agents that are currently used in the clinical setting. We have demonstrated that Chk2 favours resistance to Cisplatin; However, pre-treatment with Taxol, causes degradation of Chk2, therefore increasing sensitivity to Cisplatin. This molecular mechanism indicates that Chk2 works by inhibition of the DNA repair processes (Apoptosis, 2013 Mar; 18 (3): 347-60).. We have also shown that elevated levels of SCA favour GC invasion and metastasis, as well as regulate taxane therapy (Cell Cycle, 2014; 13 (22): 3590-601).
Additionally, our group has recently validated the function of Chk1 in relation to treatment with CG Radiation (Sci. Rep. 2016 Feb 12, 6: 21519).
Since this sensitivity increase occurs during the mitotic process, our focus now is to study the influence of Cancer Stem Cells (SCS) on GC tumorigenesis and this is therefore, the paradigm of our current research interest. Now, we focus our attention to the regulation of mitotic checkpoint proteins in GC Stem Cells and its potential influence in prognosis and Therapy Response. Finally, we are studying the role of miRNA in CIN regulation.
1. Pajuelo-Lozano N, Bargiela-Iparraguirre J, Dominguez G, Quiroga AG, Perona R, Sanchez-Perez I. XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells. Front Pharmacol. 2018 Oct 17;9:1197. doi: 10.3389/fphar.2018.01197. eCollection 2018. PMID: 30386247.
2. Echeverri M, Alvarez-Valdés A, Navas F, Perles J, Sánchez-Pérez I, Quiroga AG. Using phosphine ligands with a biological role to modulate reactivity in novel platinum complexes. R Soc Open Sci. 2018 Feb 21;5(2):171340. doi: 10.1098/rsos.171340. eCollection 2018 Feb. PMID: 29515851.
3. Larriba MJ, Ferrer-Mayorga G, Sánchez-Pérez I, Cantero R, Real FX, Del Peso L, Muñoz A, González-Sancho JM. The human PKP2/plakophilin-2 gene is induced by Wnt/β-catenin in normal and colon cancer-associated fibroblasts. Int J Cancer. 2018 Feb 15;142(4):792-804. doi: 10.1002/ijc.31104. Epub 2017 Oct 31. PMID: 29044515.
4. In vivo FRET-FLIM reveals cell-type-specific protein interactions in Arabidopsis roots. Long Y, Stahl Y, Weidtkamp-Peters S, Postma M, Zhou W, Goedhart J, Sánchez-Pérez MI, Gadella TWJ, Simon R, Scheres B, Blilou I. Nature. 2017 Aug 3;548(7665):97-102. doi: 10.1038/nature23317. Epub 2017 Jul 26.
5. Bargiela-Iparraguirre J, Prado-Marchal L, Fernandez-Fuente M, Gutierrez-González A, Moreno-Rubio J, Muñoz-Fernandez M, Sereno M, Sanchez-Prieto R, Perona R, Sanchez-Perez I. CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response Sci Rep. 2016 Feb 12;6:21519. doi: 10.1038/srep21519.
6. Madejón A, Sheldon J, Francisco-Recuero I, Perales C, Domínguez-Beato M, Lasa M, Sánchez-Perez I, Muntané J, Domingo E, García-Samaniego J, Sánchez-Pacheco A. Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity. J Hepatol. 2015 Aug;63(2):312-9. doi: 10.1016/j.jhep.2015.02.036. Epub 2015 Feb 27.
7. García-Cano J, Ambroise G, Pascual-Serra R, Carrión MC, Serrano-Oviedo L, Ortega-Muelas M, Cimas FJ, Sabater S, Ruiz-Hidalgo MJ, Sanchez Perez I, Mas A, Jalón FA, Vazquez A, Sánchez-Prieto R.. Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. Oncotarget. 2015 Jun 20;6(17):15551-65.
8. Bargiela-Iparraguirre J, Prado-Marchal L, Pajuelo-Lozano N, Jiménez B, Perona R, Sánchez-Pérez I. Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells. Cell cycle, 13(22):3590-601. doi: 10.4161/15384101.2014.962952.
9. M.L. Valero, F.J. Cimas, L. Arias, P. Melgar-Rojas, E. Garcia, J.L. Callejas-Valera, J. Garcia-Cano, L. Serrano-Oviedo, M. Angel de la Cruz-Morcillo, I. Sanchez-Perez, R. Sanchez-Prieto, E1a promotes c-Myc-dependent replicative stress: Implications in glioblastoma radiosensitization, Cell cycle, 13 (2014) 52-61.
10. A. Gutierrez-Gonzalez, C. Belda-Iniesta, J. Bargiela-Iparraguirre, G. Dominguez, P. Garcia Alfonso, R. Perona, I. Sanchez-Perez ‡, Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair, Apoptosis : an international journal on programmed cell death, 18 (2013) 347-360.
11. B. Alvarez-Castelao, C. Munoz, I. Sanchez, M. Goethals, J. Vandekerckhove, J.G. Castano, Reduced protein stability of human DJ-1/PARK7 L166P, linked to autosomal recessive Parkinson disease, is due to direct endoproteolytic cleavage by the proteasome, Biochimica et biophysica acta, 1823 (2012) 524-533.
12. V. Moncho-Amor, I. Ibanez de Caceres, E. Bandres, B. Martinez-Poveda, J.L. Orgaz, I. Sanchez-Perez, S. Zazo, A. Rovira, J. Albanell, B. Jimenez, F. Rojo, C. Belda-Iniesta, J. Garcia-Foncillas, R. Perona, DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer, Oncogene, 30 (2011) 668-678.
13. A. Peralta-Sastre, C. Manguan-Garcia, A. de Luis, C. Belda-Iniesta, S. Moreno, R. Perona, I. Sanchez-Perez. ‡ Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells, The international journal of biochemistry & cell biology, 42 (2010) 318-328.